{"url_path":"/sec/tcrt/10-q/2026/item-1","section_key":"item-1","section_title":"Item 1 Legal Proceedings","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1107421/0001193125-26-227272-index.html","accession_number":"0001193125-26-227272","cik":"0001107421","ticker":"TCRT","issuer_name":"Alaunos Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1107421/0001193125-26-227272-index.html","primary_entity_key":"0001107421","primary_entity_name":"Alaunos Therapeutics, Inc."},"word_count":129,"has_tables":true,"body_markdown":"Item 1. Legal Proceedings\n\nIn the ordinary course of business, we may periodically become subject to legal proceedings and claims arising in connection with ongoing business activities from time to time. The results of litigation and claims cannot be predicted with certainty, and unfavorable resolutions are possible and could materially affect our business, financial condition, results of operations, cash flows and prospects. In addition, regardless of the outcome, litigation could have an adverse impact on us because of defense costs, diversion of management attention and resources and other factors.\n\nWe do not have any pending litigation that, separately or in the aggregate, would, in the opinion of management, be reasonably likely to have a material adverse effect on our business, financial condition, results of operations, cash flows or prospects."}